Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: The ACCORD lipid trial

Diabetes Care

Volumn 37, Issue 3, 2014, Pages 686-693

  Linz, Peter E ^a   Lovato, Laura C ^b   Byington, Robert P ^b   O'Connor, Patrick J ^c   Leiter, Lawrence A ^d,i   Weiss, Daniel ^e   Force, Rex W ^f   Crouse, John R ^b   Ismail Beigi, Faramarz ^g   Simmons, Debra L ^h   Papademetriou, Vasilios ⁱ   Ginsberg, Henry N ⁱ   Elam, Marshall B ^j  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^c HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e Your Diabetes Endocrine Nutrition Group   (United States)

^f IDAHO STATE UNIVERSITY   (United States)

^g LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁱ GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SIMVASTATIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FOLLOW UP; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNITED STATES; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG COMBINATION; DRUG EFFECTS; DYSLIPIDEMIAS; FEMALE; GLUCOSE BLOOD LEVEL; LIPID METABOLISM; MALE; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; MALE; MIDDLE AGED; RISK FACTORS; SIMVASTATIN; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84896708504     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0790     Document Type: Article

References (30)

1. Buse JB, Bigger JT, Byington RP, et al.; ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99:21i-33i
2. Sarker A, Semple RK, Dinneen SF, O'Rahilly S, Martin SC. Severe hypo-alphalipoproteinemia during treatment with rosiglitazone. Diabetes Care 2004;27:2577-2580
3. Savage RL, Kiuru A. Thiazolidinediones and lowered HDL cholesterol. Diabetes Care 2005;28:2329-2330
4. Norm'en L, Frohlich J, Montaner J, Harris M, Elliott T, Bondy G. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 2004;27:2241-2242
5. Mymin D, Dembinski T, Friesen MH. Iatrogenic severe depression of highdensity lipoprotein cholesterol. J Clin Pharmacol 2009;49:865-871
6. Goff DC Jr., Gerstein HC, Ginsberg HN, et al.; ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:4i-20i
7. Ginsberg HN, Bonds DE, Lovato LC, et al.; ACCORD Study Group. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:56i-67i
8. Cushman WC, Grimm RH Jr., Cutler JA, et al.; ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:44i-55i
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130:461-470
10. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
11. Venero CV, Thompson PD, Fernandez AB. Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate. Am J Med 2008;121:e3-e4
12. Shetty C, BalasubramaniM, Capps N, Milles J, Ramachandran S. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. Diabet Med 2007;24:94-97
13. Schwing W, Hustak L, Taylor HC. Paradoxical severe decrease in high-density lipoprotein cholesterol due to rosiglitazone-fenofibrate interaction. Endocr Pract 2010;16:382-388
14. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002;18 (Suppl. 2):S23-S29
15. Goldberg RB, Kendall DM, Deeg MA, et al.; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-1554
16. Magee G, Sharpe PC. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon. J Clin Pathol 2009;62:250-253
17. Keidar S, Guttmann H, Stam T, Fishman I, Shapira C. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate. Pharmacoepidemiol Drug Saf 2007;16: 1192-1194
18. Gutschi LM, Malcolm JC, Favreau CM, Ooi TC. Paradoxically decreased HDLcholesterol levels associated with rosiglitazone therapy. Ann Pharmacother 2006;40:1672-1676
19. Shah A, Rader DJ, Millar JS. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010;210:35-40
20. Staels B, Auwerx J. Regulation of apo A-I gene expression by fibrates. Atherosclerosis 1998;137(Suppl.):S19-S23
21. Vu-Dac N, Chopin-Delannoy S, Gervois P, et al. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 1998;273:25713-25720
22. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 1994;269:31012-31018
23. Krause BR, Auerbach BJ. Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis. Curr Opin Investig Drugs 2001;2:375-381
24. Beghin L, Capps N, Duhal N, Davies J, Staels B, Luc G. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate. Ann Clin Biochem 1999;36: 523-525
25. Foucher C, Rattier S, Flavell DM, et al.; DAIS Investigators. Response to micronized fenofibrate treatment is associated with the peroxisome- proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics 2004;14:823-829
26. Brisson D, Ledoux K, Boss ́e Y, et al. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics 2002;12:313-320
27. Liu Y, Ordovas JM, Gao G, et al. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study. Pharmacogenet Genomics 2009;19: 161-169
28. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009;374: 126-135
29. Cavender MA, Lincoff AM. Therapeutic potential of aleglitazar, a new dual PPARa/g agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs 2010;10:209-216
30. Nichols GA, Vupputuri S, Rosales AG. Change in high-density lipoprotein cholesterol and risk of subsequent hospitalization for coronary artery disease or stroke among patients with type 2 diabetes mellitus. Am J Cardiol 2011;108: 1124-1128